Product Description
AT-9283 has been identified and developed by Astex Therapeutics via structure-based optimization of a ligand-efficient pyrazole-benzimidazole fragment. AT-9283 inhibits several important kinases, including the Aurora kinase A, Aurora kinase B, Janus kinase (Jak)2, Jak3 and Abl kinase. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/21154126/)
Mechanisms of Action: JAK2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Otsuka
Company Location:
Company Founding Year: 1921
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Preleukemia|Myelodysplastic Syndrome|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Myelofibrosis|Chronic Myeloid Leukemia|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Multiple Myeloma
Phase 1: Skin Cancer|Bone Cancer|Leukemia|Oncology Unspecified|Lymphoma, Non-Hodgkin
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2008-005542-23 |
Phase I paediatric study of AT9283 in solid tumours. | P1 |
Completed |
Oncology Unspecified |
2019-08-30 |
2022-03-12 |
Treatments |
|
NCT00985868 |
CDR0000653387 | P1 |
Completed |
Bone Cancer|Skin Cancer |
2016-01-25 |
2019-12-01 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2009-016952-36 |
Phase I study of AT9283 in paediatric acute leukaemia. | P1 |
Terminated |
Leukemia |
2014-07-01 |
2022-03-13 |
Treatments |
|
NCT01431664 |
CDR0000709775 | P1 |
Completed |
Leukemia |
2014-07-01 |
2019-03-19 |
Treatments |
|
NCT00443976 |
I181 | P1 |
Completed |
Lymphoma, Non-Hodgkin |
2010-04-09 |
2023-08-05 |
Primary Endpoints|Start Date|Treatments |
|
NCT01145989 |
I191 | P2 |
Completed |
Multiple Myeloma |
2014-10-29 |
2023-08-05 |
Primary Endpoints|Start Date|Treatments |
|
NCT00522990 |
AT9283/0002 | P2 |
Terminated |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Acute Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Lymphoid Leukemia|Preleukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Myelofibrosis |
2009-04-01 |
2019-09-07 |
Primary Endpoints|Treatments |
|
2007-005299-15 |
2007-005299-15 | P2 |
Terminated |
Myelofibrosis |
2008-04-15 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|